To improve the survival of mCRPC patients, treatment combinations (such as immunotherapy and PARPi) have been increasingly tested; however, few studies simultaneously tested PARPi and drugs affecting the PD-1/PD-L1 pathway; combined analysis of the BRCA and PD-L1 status was rarely conducted in PC patients [7,8,9,19,23,53,56,92]. This evidence concerns the gene PDCD1 and pachyonychia congenita.